MYLAN-VORICONAZOLE DIN 02399989
Health Canada record
| Active ingredient(s) | VORICONAZOLE 200 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J02AC03 VORICONAZOLE |
| Original market date | |
| Current status date | 11-Jan-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mylan Pharmaceuticals ULC — licence 101774, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VORICONAZOLE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02451387 | AURO-VORICONAZOLE | AURO PHARMA INC | Tablet | VORICONAZOLE 50 MG | Approved |
| 02451395 | AURO-VORICONAZOLE | AURO PHARMA INC | Tablet | VORICONAZOLE 200 MG | Approved |
| 02525798 | JAMP VORICONAZOLE | JAMP PHARMA CORPORATION | Tablet | VORICONAZOLE 200 MG | Marketed |
| 02525771 | JAMP VORICONAZOLE | JAMP PHARMA CORPORATION | Tablet | VORICONAZOLE 50 MG | Marketed |
| 02457709 | MED-VORICONAZOLE | GENERIC MEDICAL PARTNERS INC | Tablet | VORICONAZOLE 200 MG | Approved |
| 02399245 | SANDOZ VORICONAZOLE | SANDOZ CANADA INCORPORATED | Tablet | VORICONAZOLE 50 MG | Marketed |
| 02399253 | SANDOZ VORICONAZOLE | SANDOZ CANADA INCORPORATED | Tablet | VORICONAZOLE 200 MG | Marketed |
| 02256460 | VFEND | PFIZER CANADA ULC | Tablet | VORICONAZOLE 50 MG | Marketed |
| 02256479 | VFEND | PFIZER CANADA ULC | Tablet | VORICONAZOLE 200 MG | Marketed |
| 02279991 | VFEND | PFIZER CANADA ULC | Powder For Suspension | VORICONAZOLE 200 MG | Marketed |
| 02256487 | VFEND | PFIZER CANADA ULC | Powder For Solution | VORICONAZOLE 200 MG | Marketed |
| 02544350 | VORICONAZOLE FOR INJECTION | FORMATIVE PHARMA INC. | Powder For Solution | VORICONAZOLE 200 MG | Approved |
| 02381966 | VORICONAZOLE FOR INJECTION | SANDOZ CANADA INCORPORATED | Powder For Solution | VORICONAZOLE 200 MG | Marketed |
| 02467852 | VORICONAZOLE FOR INJECTION | PHARMARIS CANADA INC | Powder For Solution | VORICONAZOLE 200 MG | Approved |
| 02477696 | VORICONAZOLE FOR INJECTION | JAMP PHARMA CORPORATION | Powder For Solution | VORICONAZOLE 200 MG | Marketed |
| 02486695 | VORICONAZOLE FOR INJECTION | AURO PHARMA INC | Powder For Solution | VORICONAZOLE 200 MG | Approved |
| 02493829 | VORICONAZOLE FOR INJECTION | FRESENIUS KABI CANADA LTD | Powder For Solution | VORICONAZOLE 200 MG | Marketed |
| 02542994 | VORICONAZOLE FOR INJECTION | EUGIA PHARMA INC. | Powder For Solution | VORICONAZOLE 200 MG | Approved |
| 02431998 | ACH-VORICONAZOLE | ACCORD HEALTHCARE INC | Tablet | VORICONAZOLE 50 MG | Cancelled Pre Market |
| 02432005 | ACH-VORICONAZOLE | ACCORD HEALTHCARE INC | Tablet | VORICONAZOLE 200 MG | Cancelled Pre Market |
| 02409674 | APO-VORICONAZOLE | APOTEX INC | Tablet | VORICONAZOLE 50 MG | Dormant |
| 02409682 | APO-VORICONAZOLE | APOTEX INC | Tablet | VORICONAZOLE 200 MG | Dormant |
| 02399962 | MYLAN-VORICONAZOLE | MYLAN PHARMACEUTICALS ULC | Tablet | VORICONAZOLE 50 MG | Cancelled Pre Market |
| 02436353 | PMS-VORICONAZOLE | PHARMASCIENCE INC | Powder For Solution | VORICONAZOLE 200 MG | Cancelled Pre Market |
| 02396866 | TEVA-VORICONAZOLE | TEVA CANADA LIMITED | Tablet | VORICONAZOLE 50 MG | Cancelled Post Market |
| 02396874 | TEVA-VORICONAZOLE | TEVA CANADA LIMITED | Tablet | VORICONAZOLE 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15456 | 2014-03-31 | Abbreviated New Drug Submission (ANDS) |
International API supply for VORICONAZOLE
17 valid EDQM Certificates of Suitability from 17 holders. 24 active FDA Drug Master Files.
Request a quote for MYLAN-VORICONAZOLE